Generated by AI
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for severe genetic diseases. Its programs are designed to upregulate protein expression and address the underlying cause of disorders linked to insufficient protein production. The company’s portfolio centers on precision therapies for rare neuromuscular, neurological, and other haploinsufficiency-related conditions, with a strong emphasis on antisense oligonucleotide approaches and targeted gene output modulation. Stoke Therapeutics operates in the genetic medicines and rare disease markets, where its research platform supports the discovery and development of treatments intended to restore healthier levels of naturally occurring proteins. Headquartered in Bedford, Massachusetts, Stoke Therapeutics plays a specialized role in advancing novel therapeutic approaches for patients with complex inherited diseases.
Website45 Wiggins Avenue
Bedford, MA, 01730
United States
The latest articles about STOK.
Summary of May 12's posts. Generated by AI.
Summary of Mar 28's posts. Generated by AI.
Summary of May 11's posts. Generated by AI.
Investors talking about STOK also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.